Vinay Prasad, a key figure at the Food and Drug Administration, found himself in a challenging position. His team members were leaking information to the press, causing internal turmoil. Additionally, he faced criticism from various fronts, including President Trump’s allies, Democrats, and anti-vaccine advocates.
In an effort to address the mounting backlash, Prasad composed an email to his team on a Saturday evening, which was later obtained by STAT. He emphasized that the decision to crack down on a specific gene therapy product was not solely his own, but rather based on a collective scientific consensus within the agency.
“The motivation behind our actions is solely focused on what we believe is in the best interest of the public – ensuring an accurate assessment of the benefits and risks involved,” Prasad stated in his email.
However, as the situation unfolded, access to the full article on this topic is restricted to STAT+ subscribers. To unlock this article and gain access to exclusive content, in-depth analysis, newsletters, premium events, and news alerts, individuals can explore the various subscription plans available on the STAT platform.
By subscribing to STAT+, readers can stay informed about critical developments within the FDA and gain valuable insights into the complex landscape of healthcare regulation. Don’t miss out on this opportunity to delve deeper into the issues at hand and stay ahead of the curve.
